Invivyd, Inc. (IVVD)

Market Cap	566.49M
Revenue (ttm)	50.04M
Net Income (ttm)	-59.86M
Shares Out	233.12M
EPS (ttm)	-0.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,758,711
Open	2.370
Previous Close	2.330
Day's Range	2.360 - 2.455
52-Week Range	0.355 - 3.070
Beta	0.64
Analysts	Strong Buy
Price Target	8.33 (+242.8%)
Earnings Date	Nov 6, 2025

About IVVD

Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company’s pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which is in preclinical studies for the prevention or treatment of COVID-19; and Adintrevimab that is in phase 2/3 clinical trials for the prevention and trea...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 6, 2021
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: IVVD
• Website: https://invivyd.com

Analyst Summary

According to 4 analysts, the average rating for IVVD stock is "Strong Buy." The 12-month stock price target is $8.33, which is an increase of 242.80% from the latest price.

Price Target

$8.33

(242.80% upside)

Analyst Consensus: Strong Buy